◆ NeutralELAB

NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

GlobeNewswire Inc.·
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

NorthStrive Biosciences announced plans to initiate an independent flow cytometry (FACS) analysis program to characterize EL-22, an engineered Lactobacillus casei-based therapeutic candidate designed to preserve muscle during weight loss treatments. The study will quantify latent myostatin antigen expression on NorthStrive-manufactured cells and establish comparability against material previously manufactured by MOA Life Plus Co. Ltd., strengthening product identity and manufacturing consistency for future IND-enabling development.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence